ClinicalTrials.gg
CompletedNCT01456897Updated Dec 30, 2019Results posted

A Long-term Trial of OPC-34712 in Patients With Schizophrenia

A Phase 3 interventional study of OPC-34712 in Schizophrenia, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-12-30.

Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
282
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 28 studies testing brexpiprazole in Schizophrenia — 1 open to participants now, 1 under way, none of them phase 3. brexpiprazole · Schizophrenia.

Enrollment
11th of 28
282 · median 155
Started
2011
with 6 others
Phase 3
16 of 28
none open now
Registered
9th of 28
by date
Lead sponsor
2 of 28
Otsuka Pharmaceutical Co., Ltd.

Among the 28 studies testing brexpiprazole in Schizophrenia, this one is the 11th largest by enrollment, is one of 7 that started in 2011, is one of 16 in phase 3, and was the 9th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

1 of the 28 studies testing brexpiprazole in Schizophrenia is open now. Recruiting first, the newest first:

About brexpiprazole

brexpiprazole: first FDA approval 2015 (REXULTI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing brexpiprazole in Schizophrenia, or all of them as a file.
02

Study summary

To investigate the safety and efficacy of long-term administration of OPC-34712 in patients with schizophrenia.

03

Conditions studied

  • Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients age 18 years or older (at time of ) diagnosed with schizophrenia based on diagnostic criteria
  • Outpatients who are receiving an oral antipsychotic treatment (other than clozapine), who are considered to require maintenance therapy using antipsychotics, and for whom monotherapy with OPC-34712 is considered feasible

Exclusion criteria

Exclusion Criteria:

  • Female patients who are breastfeeding or who have a positive pregnancy test (urine) result prior to receiving medicinal product
  • Patients who are diagnosed with a disease other than schizophrenia (schizoaffective disorder, major depressive disorder, bipolar disorder, posttraumatic stress disorder, anxiety disorder, delirium, dementia, amnesia, or other cognitive disorder) based on current Axis Ι criteria, or who are diagnosed with a personality disorder (borderline, paranoid, histrionic, schizotypal, schizoid, or antisocial)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
282 participants (actual)

Study arms

  • Experimental
    OPC-34712

    Drug: OPC-34712

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Adverse Events

    A treatment-emergent adverse event (TEAE) is defined as an AE that started after start of investigational medicinal product (IMP) treatment.

    Time frame: From Baseline up to 52 Weeks

Secondary outcomes

  1. Mean Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score

    The PANSS consisted of 3 subscales with 30 symptom constructs (positive subscale (7): delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/perseckion, and hostility; negative subscale (7): blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity and conversation flow, stereotyped thinking and general psychopathology subscale (16): somatic concern, anxiety, guilt feelings, tension, mannerisms and posturing, depression, motor retardation, uncooperativeness, unusual thought content, disorientation, poor attention, lack of judgment and insight, disturbance of volition, poor impulse control, preoccupation, and active social avoidance). Severity was rated on 7-point scale with scores 1 (absence) \& 7 (extremely severe). The PANSS Total score ranged from 7 (best possible outcome) to 210 (worst possible outcome).

    Time frame: From Baseline up to 52 Weeks including Week24, Week52, and Last Visit(LOCF)

  2. Mean Change From Baseline in PANSS Positive Subscale Score

    The PANSS consisted of three subscales that contained a total of 30 symptom constructs. For each symptom construct, severity is rated on a 7-point scale, with a score of 1 indicated the absence of symptoms and a score of 7 indicated extremely severe symptoms. In PANSS positive subscale, the 7 positive symptom constructs were: delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. The PANSS positive subscale score ranged from 7 (best possible outcome) to 49 (worst possible outcome).

    Time frame: From Baseline up to 52 Weeks including Week24, Week52, and Last Visit(LOCF)

  3. Mean Change From Baseline in PANSS Negative Subscale Score

    The PANSS consisted of three subscales that contained a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicated the absence of symptoms and a score of 7 indicated extremely severe symptoms. In PANSS negative subscale the severity was rated for the following 7 negative symptom constructs: blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking. The PANSS negative subscale score ranged from 7 (best possible outcome) to 49 (worst possible outcome).

    Time frame: From Baseline up to 52 Weeks including Week24, Week52, and Last Visit(LOCF)

  4. Mean Change From Baseline in Clinical Global Impression-Severity of Illness (CGI-S)

    Severity of illness for each participant was rated using the CGI-S, which was the secondary efficacy endpoint. To perform this assessment, the study physician answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" Response choices included: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.

    Time frame: From Baseline up to 52 Weeks including Week24, Week52, and Last Visit(LOCF)

  5. Mean Clinical Global Impression - Global Improvement(CGI-I)

    The efficacy of trial medication was rated for each participant using the CGI-I. The study physician would rate the participant's total improvement whether or not it is due entirely to drug treatment. All responses were compared to the participant's condition at Baseline prior to the first dose of study medication. Response choices included: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse.

    Time frame: From Baseline up to 52 Weeks including Week24, Week52, and Last Visit(LOCF)

07

Results

Posted Dec 30, 2019

Participant flow

Participant flow — Overall Study
MilestoneNew SubjectsRollover Subjects
Started18498
Completed10941
Not completed7557
Withdrew: Adverse event1922
Withdrew: Protocol violation34
Withdrew: Physician decision53
Withdrew: Withdrawal by subject4417
Withdrew: Lack of efficacy411

Outcome measures

PrimaryPercentage of Participants With Adverse Events

A treatment-emergent adverse event (TEAE) is defined as an AE that started after start of investigational medicinal product (IMP) treatment.

Time frame:
From Baseline up to 52 Weeks
Reported as:
Count of participants · Participants
Percentage of Participants With Adverse Events
ParticipantsNew SubjectsRollover Subjects
Treatment-Emergent Adverse Events (TEAE)15679
Potentially Drug-related TEAE9538
Death00
SAE1918
Severe Treatment-Emergent Adverse Event87
Discontinued Due to Adverse Events2023
SecondaryMean Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score

The PANSS consisted of 3 subscales with 30 symptom constructs (positive subscale (7): delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/perseckion, and hostility; negative subscale (7): blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity and conversation flow, stereotyped thinking and general psychopathology subscale (16): somatic concern, anxiety, guilt feelings, tension, mannerisms and posturing, depression, motor retardation, uncooperativeness, unusual thought content, disorientation, poor attention, lack of judgment and insight, disturbance of volition, poor impulse control, preoccupation, and active social avoidance). Severity was rated on 7-point scale with scores 1 (absence) \& 7 (extremely severe). The PANSS Total score ranged from 7 (best possible outcome) to 210 (worst possible outcome).

Time frame:
From Baseline up to 52 Weeks including Week24, Week52, and Last Visit(LOCF)
Reported as:
Mean · units on a scale
Mean Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score
units on a scaleNew SubjectsRollover Subjects
Week24-5.31 ± 9.00-7.20 ± 12.59
Week52-7.01 ± 10.56-9.44 ± 15.16
Last Visit-3.11 ± 12.76-2.58 ± 15.56
SecondaryMean Change From Baseline in PANSS Positive Subscale Score

The PANSS consisted of three subscales that contained a total of 30 symptom constructs. For each symptom construct, severity is rated on a 7-point scale, with a score of 1 indicated the absence of symptoms and a score of 7 indicated extremely severe symptoms. In PANSS positive subscale, the 7 positive symptom constructs were: delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. The PANSS positive subscale score ranged from 7 (best possible outcome) to 49 (worst possible outcome).

Time frame:
From Baseline up to 52 Weeks including Week24, Week52, and Last Visit(LOCF)
Reported as:
Mean · units on a scale
Mean Change From Baseline in PANSS Positive Subscale Score
units on a scaleNew SubjectsRollover Subjects
WEEK24-1.09 ± 2.27-1.53 ± 3.40
WEEK52-1.13 ± 2.73-1.61 ± 4.41
Last Visit-0.19 ± 3.960.24 ± 4.83
SecondaryMean Change From Baseline in PANSS Negative Subscale Score

The PANSS consisted of three subscales that contained a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicated the absence of symptoms and a score of 7 indicated extremely severe symptoms. In PANSS negative subscale the severity was rated for the following 7 negative symptom constructs: blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking. The PANSS negative subscale score ranged from 7 (best possible outcome) to 49 (worst possible outcome).

Time frame:
From Baseline up to 52 Weeks including Week24, Week52, and Last Visit(LOCF)
Reported as:
Mean · units on a scale
Mean Change From Baseline in PANSS Negative Subscale Score
units on a scaleNew SubjectsRollover Subjects
Week24-1.64 ± 3.22-1.49 ± 3.84
Week52-2.27 ± 3.85-2.02 ± 4.47
Last Visit-1.43 ± 3.85-0.89 ± 3.92
SecondaryMean Change From Baseline in Clinical Global Impression-Severity of Illness (CGI-S)

Severity of illness for each participant was rated using the CGI-S, which was the secondary efficacy endpoint. To perform this assessment, the study physician answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" Response choices included: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.

Time frame:
From Baseline up to 52 Weeks including Week24, Week52, and Last Visit(LOCF)
Reported as:
Mean · units on a scale
Mean Change From Baseline in Clinical Global Impression-Severity of Illness (CGI-S)
units on a scaleNew SubjectsRollover Subjects
Week24-0.26 ± 0.71-0.20 ± 0.75
Week52-0.28 ± 0.67-0.15 ± 0.82
Last Visit-0.13 ± 0.810.03 ± 0.92
SecondaryMean Clinical Global Impression - Global Improvement(CGI-I)

The efficacy of trial medication was rated for each participant using the CGI-I. The study physician would rate the participant's total improvement whether or not it is due entirely to drug treatment. All responses were compared to the participant's condition at Baseline prior to the first dose of study medication. Response choices included: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse.

Time frame:
From Baseline up to 52 Weeks including Week24, Week52, and Last Visit(LOCF)
Reported as:
Mean · units on a scale
Mean Clinical Global Impression - Global Improvement(CGI-I)
units on a scaleNew SubjectsRollover Subjects
Week243.09 ± 0.943.16 ± 0.90
Week523.09 ± 0.913.22 ± 0.99
Last Visit3.48 ± 1.223.86 ± 1.27

Adverse events

Collected over Adverse events were monitored from signing of the informed consent form until follow-up for up to 30 days after the completion of the treatment period (52 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
New Subjects0/183 (0%)19/183 (10.4%)112/183 (61.2%)
Rollover Subjects0/98 (0%)18/98 (18.4%)50/98 (51%)
Most frequent serious events
Most frequent serious events
EventNew SubjectsRollover Subjects
SchizophreniaPsychiatric disorders17/18313/98
Gastrointestinal haemorrhageGastrointestinal disorders0/1831/98
Meningitis asepticInfections and infestations0/1831/98
Heat illnessInjury, poisoning and procedural complications0/1831/98
Toxicity to various agentsInjury, poisoning and procedural complications0/1831/98
DehydrationMetabolism and nutrition disorders1/1831/98
AkathisiaNervous system disorders1/1831/98
Extrapyramidal disorderNervous system disorders1/1830/98
Most frequent other events
Showing 10 of 11
Most frequent other events
EventNew SubjectsRollover Subjects
NasopharyngitisInfections and infestations46/18319/98
SchizophreniaPsychiatric disorders21/18313/98
HeadacheNervous system disorders19/1833/98
Weight increasedInvestigations9/18310/98
AkathisiaNervous system disorders15/1837/98
InsomniaPsychiatric disorders15/1832/98
TremorNervous system disorders4/1838/98
Back painMusculoskeletal and connective tissue disorders13/1834/98
SomnolenceNervous system disorders13/1833/98
EczemaSkin and subcutaneous tissue disorders5/1836/98

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)New SubjectsRollover SubjectsTotal
<=18 years000
Between 18 and 65 years15598253
>=65 years29029
Age, Continuous
Age, Continuous(years)New SubjectsRollover SubjectsTotal
Mean45.5 ± 14.742.5 ± 12.544.4 ± 14.0
Sex: Female, Male
Sex: Female, Male(Participants)New SubjectsRollover SubjectsTotal
Female9458152
Male9040130
Region of Enrollment
Region of Enrollment(participants)New SubjectsRollover SubjectsTotal
Japan18498282
08

Study locations

1 site
  • Kanto Region, Japan
09

References and documents

Publications

  • Ishigooka J, Usami T, Iwashita S, Kojima Y, Matsuo S. Post-hoc analysis investigating the safety and efficacy of brexpiprazole in Japanese patients with schizophrenia who were switched from other antipsychotics in a long-term study (Secondary Publication). Neuropsychopharmacol Rep. 2020 Jun;40(2):122-129. doi: 10.1002/npr2.12107. Epub 2020 Apr 15. PubMed 32297486 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2011 and a primary completion of May 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2019, 4 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2011
First posted
Oct 21, 2011
Start
Oct 2011
Primary completionActual
May 2015
Results first posted
Dec 30, 2019
Last update
Dec 30, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 30, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01456897
Responsible party
Sponsor
First posted
Oct 21, 2011
Start date
Oct 2011
Primary completion
May 2015
Results posted
Dec 30, 2019
Last update
Dec 30, 2019

Study contacts

Kyoji Imaoka, Operating Officer
study director · Otsuka Pharmaceutical Co., Ltd.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brexpiprazole

Start the discussion